<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00785577</url>
  </required_header>
  <id_info>
    <org_study_id>11977</org_study_id>
    <secondary_id>H8C-MC-LQBF</secondary_id>
    <nct_id>NCT00785577</nct_id>
  </id_info>
  <brief_title>A Study for Treatment of Pain in Patients With Diabetic Neuropathy.</brief_title>
  <official_title>A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Painful Diabetic Neuropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether a new treatment will be safe and effective in
      treating pain. Patients with diabetic peripheral neuropathy will be included.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>This scale measured 24-hour APS scores. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). Least Squares (LS) Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Mean Night Pain Severity Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>This scale measured night pain APS scores. Data were recorded daily on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Mean Worst Daily Pain Severity Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>This scale measured worst pain APS scores. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 30% Reduction in Weekly Mean 24-hour Average Pain Severity (APS) Score</measure>
    <time_frame>Baseline through 5 weeks</time_frame>
    <description>This scale measured the number of participants with a 30% reduction in weekly mean 24-hour APS score from baseline to endpoint. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Brief Pain Inventory - Interference (BPI-I) Subscale Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>Average BPI-I measured self-reported degree of pain interference on function. Interference scores: 0 (does not interfere) to 10 (completely interferes) on each question assessing interference of pain in past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Average interference = average of non-missing scores of individual interference items. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory - Severity (BPI-S) Subscale Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>BPI-S measured self-reported severity of pain. Severity scores: 0 (no pain) to 10 (severe pain) on each question assessing worst pain, least pain, and average pain in past 24 hours, and current pain. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>CGI-S measured severity of illness at the time of assessment compared with start of treatment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) Score at 5 Weeks</measure>
    <time_frame>Week 5</time_frame>
    <description>PGI-I measured the participant's perception of improvement at the time of assessment compared with the start of treatment. The score ranged from 1 (very much better) to 7 (very much worse). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-form McGill Pain Questionnaire (SF-MPQ) Sensory Subscale Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>SF-MPQ consisted of 11 sensory descriptors describing pain that were rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores were derived from the sum of the intensity rank values of the words chosen for sensory descriptors. The SF-MPQ sensory subscale was the sum of the 11 scores (ranged from 0 to 33, with 33 being the worst). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Assessment of Sleep Questionnaire (ASQ) Total Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>ASQ consisted of 21 items (including a single item to assess overall sleep quality) and 3 subscales: Sleep Onset and Maintenance (items 1-3, 5-6, 9, 11); Sleep Experience (items 4, 7, 8, 10, 12); and Awakening Experience (items 13-20). Each item was scored on a 5-point Likert scale, ranging from 0 (no sleep at all) to 5 (a lot of sleep). Each subscale was calculated as the mean of the individual items comprising the subscale. A total ASQ score was calculated as the mean of the subscale scores; higher scores represent better sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropathy-Specific Quality of Life (NeuroQoL) Questionnaire Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>NeuroQoL had 29 items: 13 assessed specific somatic experiences (pain, lost/reduced feeling, and diffuse sensory-motor symptoms); 14 assessed specific functional, social, and emotional experiences (restrictions in daily living activities, disruptions in social relationships, and emotional distress); 2 items assessed QoL and overall satisfaction. Items reported on a 5‑point scale (never/not at all to all of the time/very much). Higher mean scores=more severe symptoms/greater disruption in functioning. First 27 items also associate with 3‑point bothersome/importance scale (1=none to 3=very).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form-36 (SF-36) Health Survey Bodily Pain Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>The SF-36 Health Status Survey was a generic, health-related scale assessing participants' quality of life on 8 domains (physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health) and 2 summary scores (mental component summary [MCS] and physical component summary [PCS]). MCS and PCS scores=0-100 (higher scores indicate better health status). Domain scores: general health=5-25; physical functioning=10-30; role-physical=4-8; role-emotional=3-6; social functioning=2-10; bodily pain=2-11; vitality=4-24; mental health=5-30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of European Quality of Life Scale - 5 Dimensions (EQ-5D) at 5 Weeks: United States Population Based Index Score</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>The EQ-5D was a generic, multidimensional, health-related, quality-of-life instrument. The profile allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score between 1 and 3 was generated for each domain. For each participant, the outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with the higher score indicating a better health state perceived by the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sheehan Disability Scale (SDS) Global Impairment Score at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>The SDS was completed by the participant and was used to assess the effect of the participant's symptoms on work/social/family life. Total scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Due to Adverse Events (AEs) During the Therapy (Double-blind) Phase and 1-Week Washout (Follow-up) Phase</measure>
    <time_frame>Baseline through 6 weeks</time_frame>
    <description>Participant discontinuation in the study due to serious and other non-serious AEs was measured during both the therapy (double-blind) phase and 1-week washout (follow-up) phase. A listing of serious and other non-serious AEs is located in the Reported Adverse Event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Treatment Emergent Abnormal High or Low Laboratory Values</measure>
    <time_frame>Baseline through 5 weeks</time_frame>
    <description>The number of participants by treatment group who had abnormal high or low laboratory values was reported by the investigator and summarized as serious adverse events (SAEs) from the &quot;Investigations&quot; system organ class during the treatment phase of the study. A listing of SAEs is located in the Reported Adverse Event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>Participants' systolic blood pressure and diastolic blood pressure were measured in millimeters of mercury (mmHg). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs: Pulse Rate at 5 Weeks</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>Pulse rate was measured in beats per minute (bpm). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Electrocardiogram Change in Heart Rate Using Bazett's (QTcB) and Fridericia's (QTcF) Formulas</measure>
    <time_frame>Baseline through 5 weeks</time_frame>
    <description>The number of participants having QTcF and QTcB change ≥ 30 msec was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Reported Hypoglycemic Events</measure>
    <time_frame>Baseline through 5 weeks</time_frame>
    <description>Percentage of participants who reported hypoglycemic (lower than normal level of blood glucose) episodes was summarized as other non-serious adverse events (AEs) from the &quot;Investigations&quot; system organ class (preferred term = hypoglycemia). A listing of AEs is located in the Reported Adverse Event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Total Quick Inventory of Depressive Symptomatology (QIDS) Score</measure>
    <time_frame>Baseline, 5 weeks</time_frame>
    <description>The QIDS was a 16-item patient-rated measure of depressive symptomatology. Each item had a 0 to 3 point scale. The total score ranged from 0 to 27 with higher scores indicative of greater severity. QIDS was calculated by summing the scores from the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) major depressive disorder criteria: depressed mood, loss of interest or pleasure, concentration/decision making, self outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, and psychomotor changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suicidal Behaviors and Ideations</measure>
    <time_frame>Baseline through week 5</time_frame>
    <description>The Columbia Suicide Severity Rating Scale (C-SSRS) captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors and ideations were provided. Suicidal behavior = a &quot;yes&quot; answer to any 1 of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation = a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions, which included the wish to be dead and 4 different categories of active suicidal ideation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Blurry or Hazy Vision Using the Subjective Vision Inventory (SVI) Question 1 (Q1) at 5 Weeks</measure>
    <time_frame>Week 5</time_frame>
    <description>This scale first asked if the participant was experiencing hazy or blurry vision or if he/she had difficulty focusing. If the answer was yes, follow-up questions rated the degree to which the issue impaired his/her ability to do work or to read.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Clearance of LY545694 (CLp) and Compound 645838 (CLm)</measure>
    <time_frame>Baseline through 5 weeks</time_frame>
    <description>Clearance is the volume of plasma cleared of study drug LY545694 (CLp) and metabolite compound 645838 (CLm) per unit time. The original PK/pharmacodynamic (PD) relationship outcome measure analysis was not conducted; therefore, only PK data were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Baseline through 5 weeks</time_frame>
    <description>Time to response=first visit achieving a 30% reduction of weekly mean 24-hour APS score. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The number of days at which 50% of the participants at risk had at least 30% response was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neurological Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline through 5 weeks</time_frame>
    <description>The total number of TEAEs (serious and non-serious) that first occurred or worsened during the treatment period) from the &quot;Nervous system disorders&quot; system organ class was summarized. A listing of serious AEs (SAEs) and other non-serious AEs is located in the Reported Adverse Event module.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Diabetic Neuropathy, Painful</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules thrice daily (TID) po for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin thrice daily (TID) oral for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6
LY545694 placebo BID po for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY545694 21 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY545694 21 milligrams (mg) BID po for 1 week
Pregabalin placebo TID po for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY545694 49 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.
Pregabalin placebo TID po for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY545694 105 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.
Pregabalin placebo TID po for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>LY545694 placebo BID po for 5 weeks
Pregabalin placebo capsules TID po for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6
LY545694 placebo BID po for 5 weeks</description>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY545694 21 mg</intervention_name>
    <description>LY545694 21 mg BID po for 1 week
Pregabalin placebo TID po for 6 weeks</description>
    <arm_group_label>LY545694 21 mg</arm_group_label>
    <other_name>LY545694</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY545694 49 mg</intervention_name>
    <description>LY545694 escalated to 49 mg BID po for 1 week during Week 2.
Pregabalin placebo TID po for 6 weeks.</description>
    <arm_group_label>LY545694 49 mg</arm_group_label>
    <other_name>LY545694</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY545694 105 mg</intervention_name>
    <description>LY545694 105 mg BID po for 5 weeks
Pregabalin placebo TID po for 6 weeks</description>
    <arm_group_label>LY545694 105 mg</arm_group_label>
    <other_name>LY545694</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have pain due to peripheral neuropathy based on disease diagnostic criteria: must have
             Type 1 or Type 2 diabetes mellitus, pain must being in the feet, with relatively
             symmetrical onset, daily pain must be present for at least 6 months, and diagnosis
             must be confirmed by a score of at least 3 on Part B of the Michigan Neuropathy
             Screening Instrument.

          -  Have stable glycemic control, and glycated hemoglobin (HbA1c) less than or equal to
             10%

          -  Mean score of at least 4 on the 24-hour average page severity assessment from (from
             daily diary) Visits 2 to 3.

          -  Fully completed daily diaries for at least 70% of the days between Visit 2 and 3.

          -  Women must test negative for a serum pregnancy test at Visit 1, and must agree to use
             medically acceptable and reliable means of birth control as determined by the
             investigator during the study and for 1 month following the last dose of study drug.

          -  Are competent and able to freely give own informed consent.

          -  Have an educational level and degree of understanding such that they can communicate
             intelligible with the investigator and study coordinator.

          -  Have been judged to be reliable and agree to keep all appointments for clinic visits,
             tests, and procedures required by the protocol.

        Exclusion Criteria:

          -  Have historical exposure to drugs known to cause neuropathy, or a history of a medical
             condition, including pernicious anemia and hypothyroidism, that could have been
             responsible for neuropathy.

          -  Have pain that cannot be clearly differentiated from or conditions that interfere with
             the assessment of diabetic neuropathy pain.

          -  Have had treatment with any centrally active neuroleptic drug within 30 days of visit
             3.

          -  Have had intolerance to pregabalin or have frequent and/or severe allergic reactions
             with multiple medications.

          -  Have current or previous (within the past 1 year) Axis 1 diagnosis of major depressive
             disorder, mania, bipolar disorder, psychosis, dysthymia, generalized anxiety disorder,
             alcohol or eating disorders according to Diagnostic and Statistical Manual of Mental
             Disorders 4th edition (DSM-IV) criteria, as determined by the investigator and
             confirmed by the Mini-International Neuropsychiatric Interview (MINI).

          -  Have a serious of unstable cardiovascular, hepatic, renal, respiratory,
             ophthalmologic, gastrointestinal, or hematologic illness, symptomatic peripheral
             vascular disease, or other medical condition that in the opinion of the investigator
             would compromise participation or be likely to lead to hospitalization during the
             course of the study.

          -  Have alanine aminotransaminase &gt; 2 times upper limit of normal at Visit 1, based on
             reference ranges of central lab.

          -  Have prior renal transplant, current renal dialysis, or serum creatinine laboratory
             values &gt; 1.5 times upper limit of normal, based on reference ranges of the central lab
             at Visit 1.

          -  Have a diagnosis or history of glaucoma.

          -  Are taking excluded medication that cannot be stopped and washed out prior to Visit 2.

          -  Have history of substance abuse or dependence within the past year, excluding nicotine
             and caffeine.

          -  Are judged clinically by the investigator to be at suicidal risk in the opinion of the
             investigator based upon clinical interview and the Columbia Suicide-Severity Rating
             Scale.

          -  Have a positive urine drug screen for any substance of abuse or excluded medication.

          -  Are unwilling or unable to comply with the use of a data collection device to directly
             record data from the subject (daily diary).

          -  Are pregnant or breast-feeding.

          -  Are investigator site personnel directly affiliated with this study and/or their
             immediate families.

          -  Are Lilly employees.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Have a history of recurrent seizures other than febrile seizures.

          -  Have a history of severe gastroparesis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20217</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hato Rey</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <results_first_submitted>August 25, 2011</results_first_submitted>
  <results_first_submitted_qc>April 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 31, 2012</results_first_posted>
  <disposition_first_submitted>February 25, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 25, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 11, 2011</disposition_first_posted>
  <last_update_submitted>April 30, 2012</last_update_submitted>
  <last_update_submitted_qc>April 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study Period 1 was an up to 5-week screening phase when participants stopped use of excluded medications (525 participants entered; 252 discontinued ). Study Period 2 was a 5-week, double-blind therapy period when randomization and dispensing of study drug occurred. Study Period 3 was a 1-week washout phase when all study medication was stopped.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Pregabalin</title>
          <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
        </group>
        <group group_id="P3">
          <title>LY545694 21 mg</title>
          <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
        </group>
        <group group_id="P4">
          <title>LY545694 49 mg</title>
          <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
        </group>
        <group group_id="P5">
          <title>LY545694 105 mg</title>
          <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Period 2: Therapy Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Exclusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period 3: 1-Week Washout Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Pregabalin</title>
          <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
        </group>
        <group group_id="B3">
          <title>LY545694 21 mg</title>
          <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
        </group>
        <group group_id="B4">
          <title>LY545694 49 mg</title>
          <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
        </group>
        <group group_id="B5">
          <title>LY545694 105 mg</title>
          <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="89"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="47"/>
            <count group_id="B6" value="273"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.32" spread="10.00"/>
                    <measurement group_id="B2" value="56.89" spread="8.19"/>
                    <measurement group_id="B3" value="56.95" spread="8.35"/>
                    <measurement group_id="B4" value="58.59" spread="7.71"/>
                    <measurement group_id="B5" value="56.47" spread="7.77"/>
                    <measurement group_id="B6" value="56.62" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks</title>
        <description>This scale measured 24-hour APS scores. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). Least Squares (LS) Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure. Last observation carried forward (LOCF) was conducted on the primary efficacy measure modified ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) twice daily (BID) oral (po) for 1 week.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg twice daily (BID) oral (po) during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg twice daily (BID) oral (po) during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks</title>
          <description>This scale measured 24-hour APS scores. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). Least Squares (LS) Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure. Last observation carried forward (LOCF) was conducted on the primary efficacy measure modified ITT population.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="0.22"/>
                    <measurement group_id="O2" value="-2.22" spread="0.36"/>
                    <measurement group_id="O3" value="-2.45" spread="0.32"/>
                    <measurement group_id="O4" value="-2.42" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weekly Mean Night Pain Severity Score at 5 Weeks</title>
        <description>This scale measured night pain APS scores. Data were recorded daily on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Mean Night Pain Severity Score at 5 Weeks</title>
          <description>This scale measured night pain APS scores. Data were recorded daily on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="0.23"/>
                    <measurement group_id="O2" value="-2.75" spread="0.33"/>
                    <measurement group_id="O3" value="-2.25" spread="0.37"/>
                    <measurement group_id="O4" value="-2.54" spread="0.33"/>
                    <measurement group_id="O5" value="-2.21" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weekly Mean Worst Daily Pain Severity Score at 5 Weeks</title>
        <description>This scale measured worst pain APS scores. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Mean Worst Daily Pain Severity Score at 5 Weeks</title>
          <description>This scale measured worst pain APS scores. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="0.25"/>
                    <measurement group_id="O2" value="-2.87" spread="0.35"/>
                    <measurement group_id="O3" value="-2.57" spread="0.40"/>
                    <measurement group_id="O4" value="-2.77" spread="0.35"/>
                    <measurement group_id="O5" value="-2.67" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 30% Reduction in Weekly Mean 24-hour Average Pain Severity (APS) Score</title>
        <description>This scale measured the number of participants with a 30% reduction in weekly mean 24-hour APS score from baseline to endpoint. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain).</description>
        <time_frame>Baseline through 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure. LOCF was conducted on the primary efficacy measure modified ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) twice daily (BID) oral (po) for 1 week.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg twice daily (BID) oral (po) during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg twice daily (BID) oral (po) during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 30% Reduction in Weekly Mean 24-hour Average Pain Severity (APS) Score</title>
          <description>This scale measured the number of participants with a 30% reduction in weekly mean 24-hour APS score from baseline to endpoint. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain).</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure. LOCF was conducted on the primary efficacy measure modified ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Brief Pain Inventory - Interference (BPI-I) Subscale Score at 5 Weeks</title>
        <description>Average BPI-I measured self-reported degree of pain interference on function. Interference scores: 0 (does not interfere) to 10 (completely interferes) on each question assessing interference of pain in past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Average interference = average of non-missing scores of individual interference items. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Brief Pain Inventory - Interference (BPI-I) Subscale Score at 5 Weeks</title>
          <description>Average BPI-I measured self-reported degree of pain interference on function. Interference scores: 0 (does not interfere) to 10 (completely interferes) on each question assessing interference of pain in past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Average interference = average of non-missing scores of individual interference items. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" spread="0.25"/>
                    <measurement group_id="O2" value="-2.81" spread="0.34"/>
                    <measurement group_id="O3" value="-2.31" spread="0.39"/>
                    <measurement group_id="O4" value="-2.73" spread="0.34"/>
                    <measurement group_id="O5" value="-2.30" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory - Severity (BPI-S) Subscale Score at 5 Weeks</title>
        <description>BPI-S measured self-reported severity of pain. Severity scores: 0 (no pain) to 10 (severe pain) on each question assessing worst pain, least pain, and average pain in past 24 hours, and current pain. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory - Severity (BPI-S) Subscale Score at 5 Weeks</title>
          <description>BPI-S measured self-reported severity of pain. Severity scores: 0 (no pain) to 10 (severe pain) on each question assessing worst pain, least pain, and average pain in past 24 hours, and current pain. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPI-S Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="0.29"/>
                    <measurement group_id="O2" value="-3.54" spread="0.40"/>
                    <measurement group_id="O3" value="-3.49" spread="0.47"/>
                    <measurement group_id="O4" value="-2.94" spread="0.41"/>
                    <measurement group_id="O5" value="-3.13" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI-S Least Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="0.26"/>
                    <measurement group_id="O2" value="-2.44" spread="0.35"/>
                    <measurement group_id="O3" value="-1.99" spread="0.40"/>
                    <measurement group_id="O4" value="-2.09" spread="0.36"/>
                    <measurement group_id="O5" value="-1.54" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI-S Average Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="0.26"/>
                    <measurement group_id="O2" value="-2.92" spread="0.36"/>
                    <measurement group_id="O3" value="-2.79" spread="0.41"/>
                    <measurement group_id="O4" value="-2.50" spread="0.36"/>
                    <measurement group_id="O5" value="-2.25" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI-S Current Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="0.28"/>
                    <measurement group_id="O2" value="-3.06" spread="0.38"/>
                    <measurement group_id="O3" value="-2.66" spread="0.44"/>
                    <measurement group_id="O4" value="-2.98" spread="0.39"/>
                    <measurement group_id="O5" value="-2.51" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 5 Weeks</title>
        <description>CGI-S measured severity of illness at the time of assessment compared with start of treatment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 5 Weeks</title>
          <description>CGI-S measured severity of illness at the time of assessment compared with start of treatment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.11"/>
                    <measurement group_id="O2" value="-1.02" spread="0.15"/>
                    <measurement group_id="O3" value="-1.28" spread="0.18"/>
                    <measurement group_id="O4" value="-1.07" spread="0.15"/>
                    <measurement group_id="O5" value="-1.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) Score at 5 Weeks</title>
        <description>PGI-I measured the participant's perception of improvement at the time of assessment compared with the start of treatment. The score ranged from 1 (very much better) to 7 (very much worse). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Week 5</time_frame>
        <population>The analysis population was a modified intent to treat (ITT) population defined as participants who received either study drug with only postbaseline data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) Score at 5 Weeks</title>
          <description>PGI-I measured the participant's perception of improvement at the time of assessment compared with the start of treatment. The score ranged from 1 (very much better) to 7 (very much worse). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent to treat (ITT) population defined as participants who received either study drug with only postbaseline data collected.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="0.13"/>
                    <measurement group_id="O2" value="2.28" spread="0.18"/>
                    <measurement group_id="O3" value="2.37" spread="0.20"/>
                    <measurement group_id="O4" value="2.63" spread="0.18"/>
                    <measurement group_id="O5" value="2.41" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-form McGill Pain Questionnaire (SF-MPQ) Sensory Subscale Score at 5 Weeks</title>
        <description>SF-MPQ consisted of 11 sensory descriptors describing pain that were rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores were derived from the sum of the intensity rank values of the words chosen for sensory descriptors. The SF-MPQ sensory subscale was the sum of the 11 scores (ranged from 0 to 33, with 33 being the worst). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-form McGill Pain Questionnaire (SF-MPQ) Sensory Subscale Score at 5 Weeks</title>
          <description>SF-MPQ consisted of 11 sensory descriptors describing pain that were rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores were derived from the sum of the intensity rank values of the words chosen for sensory descriptors. The SF-MPQ sensory subscale was the sum of the 11 scores (ranged from 0 to 33, with 33 being the worst). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.20" spread="0.73"/>
                    <measurement group_id="O2" value="-8.60" spread="1.01"/>
                    <measurement group_id="O3" value="-8.93" spread="1.20"/>
                    <measurement group_id="O4" value="-8.95" spread="1.02"/>
                    <measurement group_id="O5" value="-7.89" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Assessment of Sleep Questionnaire (ASQ) Total Score at 5 Weeks</title>
        <description>ASQ consisted of 21 items (including a single item to assess overall sleep quality) and 3 subscales: Sleep Onset and Maintenance (items 1-3, 5-6, 9, 11); Sleep Experience (items 4, 7, 8, 10, 12); and Awakening Experience (items 13-20). Each item was scored on a 5-point Likert scale, ranging from 0 (no sleep at all) to 5 (a lot of sleep). Each subscale was calculated as the mean of the individual items comprising the subscale. A total ASQ score was calculated as the mean of the subscale scores; higher scores represent better sleep.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Assessment of Sleep Questionnaire (ASQ) Total Score at 5 Weeks</title>
          <description>ASQ consisted of 21 items (including a single item to assess overall sleep quality) and 3 subscales: Sleep Onset and Maintenance (items 1-3, 5-6, 9, 11); Sleep Experience (items 4, 7, 8, 10, 12); and Awakening Experience (items 13-20). Each item was scored on a 5-point Likert scale, ranging from 0 (no sleep at all) to 5 (a lot of sleep). Each subscale was calculated as the mean of the individual items comprising the subscale. A total ASQ score was calculated as the mean of the subscale scores; higher scores represent better sleep.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.08"/>
                    <measurement group_id="O2" value="0.88" spread="0.11"/>
                    <measurement group_id="O3" value="0.67" spread="0.13"/>
                    <measurement group_id="O4" value="0.51" spread="0.12"/>
                    <measurement group_id="O5" value="0.55" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neuropathy-Specific Quality of Life (NeuroQoL) Questionnaire Score at 5 Weeks</title>
        <description>NeuroQoL had 29 items: 13 assessed specific somatic experiences (pain, lost/reduced feeling, and diffuse sensory-motor symptoms); 14 assessed specific functional, social, and emotional experiences (restrictions in daily living activities, disruptions in social relationships, and emotional distress); 2 items assessed QoL and overall satisfaction. Items reported on a 5‑point scale (never/not at all to all of the time/very much). Higher mean scores=more severe symptoms/greater disruption in functioning. First 27 items also associate with 3‑point bothersome/importance scale (1=none to 3=very).</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy-Specific Quality of Life (NeuroQoL) Questionnaire Score at 5 Weeks</title>
          <description>NeuroQoL had 29 items: 13 assessed specific somatic experiences (pain, lost/reduced feeling, and diffuse sensory-motor symptoms); 14 assessed specific functional, social, and emotional experiences (restrictions in daily living activities, disruptions in social relationships, and emotional distress); 2 items assessed QoL and overall satisfaction. Items reported on a 5‑point scale (never/not at all to all of the time/very much). Higher mean scores=more severe symptoms/greater disruption in functioning. First 27 items also associate with 3‑point bothersome/importance scale (1=none to 3=very).</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.11"/>
                    <measurement group_id="O2" value="-0.49" spread="0.15"/>
                    <measurement group_id="O3" value="-0.58" spread="0.16"/>
                    <measurement group_id="O4" value="-0.59" spread="0.15"/>
                    <measurement group_id="O5" value="-0.31" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form-36 (SF-36) Health Survey Bodily Pain Score at 5 Weeks</title>
        <description>The SF-36 Health Status Survey was a generic, health-related scale assessing participants’ quality of life on 8 domains (physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health) and 2 summary scores (mental component summary [MCS] and physical component summary [PCS]). MCS and PCS scores=0-100 (higher scores indicate better health status). Domain scores: general health=5-25; physical functioning=10-30; role-physical=4-8; role-emotional=3-6; social functioning=2-10; bodily pain=2-11; vitality=4-24; mental health=5-30.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form-36 (SF-36) Health Survey Bodily Pain Score at 5 Weeks</title>
          <description>The SF-36 Health Status Survey was a generic, health-related scale assessing participants’ quality of life on 8 domains (physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health) and 2 summary scores (mental component summary [MCS] and physical component summary [PCS]). MCS and PCS scores=0-100 (higher scores indicate better health status). Domain scores: general health=5-25; physical functioning=10-30; role-physical=4-8; role-emotional=3-6; social functioning=2-10; bodily pain=2-11; vitality=4-24; mental health=5-30.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="0.94"/>
                    <measurement group_id="O2" value="10.70" spread="1.26"/>
                    <measurement group_id="O3" value="8.16" spread="1.32"/>
                    <measurement group_id="O4" value="5.78" spread="1.24"/>
                    <measurement group_id="O5" value="6.33" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of European Quality of Life Scale - 5 Dimensions (EQ-5D) at 5 Weeks: United States Population Based Index Score</title>
        <description>The EQ-5D was a generic, multidimensional, health-related, quality-of-life instrument. The profile allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score between 1 and 3 was generated for each domain. For each participant, the outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with the higher score indicating a better health state perceived by the participant.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of European Quality of Life Scale - 5 Dimensions (EQ-5D) at 5 Weeks: United States Population Based Index Score</title>
          <description>The EQ-5D was a generic, multidimensional, health-related, quality-of-life instrument. The profile allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score between 1 and 3 was generated for each domain. For each participant, the outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with the higher score indicating a better health state perceived by the participant.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.02"/>
                    <measurement group_id="O2" value="0.09" spread="0.02"/>
                    <measurement group_id="O3" value="0.11" spread="0.02"/>
                    <measurement group_id="O4" value="0.05" spread="0.02"/>
                    <measurement group_id="O5" value="0.07" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sheehan Disability Scale (SDS) Global Impairment Score at 5 Weeks</title>
        <description>The SDS was completed by the participant and was used to assess the effect of the participant's symptoms on work/social/family life. Total scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sheehan Disability Scale (SDS) Global Impairment Score at 5 Weeks</title>
          <description>The SDS was completed by the participant and was used to assess the effect of the participant's symptoms on work/social/family life. Total scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" spread="0.70"/>
                    <measurement group_id="O2" value="-2.58" spread="0.94"/>
                    <measurement group_id="O3" value="-2.63" spread="0.99"/>
                    <measurement group_id="O4" value="-1.97" spread="0.95"/>
                    <measurement group_id="O5" value="-3.04" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Due to Adverse Events (AEs) During the Therapy (Double-blind) Phase and 1-Week Washout (Follow-up) Phase</title>
        <description>Participant discontinuation in the study due to serious and other non-serious AEs was measured during both the therapy (double-blind) phase and 1-week washout (follow-up) phase. A listing of serious and other non-serious AEs is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline through 6 weeks</time_frame>
        <population>The safety analysis population included all 273 participants randomized to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Due to Adverse Events (AEs) During the Therapy (Double-blind) Phase and 1-Week Washout (Follow-up) Phase</title>
          <description>Participant discontinuation in the study due to serious and other non-serious AEs was measured during both the therapy (double-blind) phase and 1-week washout (follow-up) phase. A listing of serious and other non-serious AEs is located in the Reported Adverse Event module.</description>
          <population>The safety analysis population included all 273 participants randomized to study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Therapy (Double-blind) Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Week Washout (Follow-up) Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Treatment Emergent Abnormal High or Low Laboratory Values</title>
        <description>The number of participants by treatment group who had abnormal high or low laboratory values was reported by the investigator and summarized as serious adverse events (SAEs) from the &quot;Investigations&quot; system organ class during the treatment phase of the study. A listing of SAEs is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline through 5 weeks</time_frame>
        <population>The safety analysis population included all 273 participants randomized to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Treatment Emergent Abnormal High or Low Laboratory Values</title>
          <description>The number of participants by treatment group who had abnormal high or low laboratory values was reported by the investigator and summarized as serious adverse events (SAEs) from the &quot;Investigations&quot; system organ class during the treatment phase of the study. A listing of SAEs is located in the Reported Adverse Event module.</description>
          <population>The safety analysis population included all 273 participants randomized to study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase (ALT) abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase (AST) abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure at 5 Weeks</title>
        <description>Participants' systolic blood pressure and diastolic blood pressure were measured in millimeters of mercury (mmHg). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure at 5 Weeks</title>
          <description>Participants' systolic blood pressure and diastolic blood pressure were measured in millimeters of mercury (mmHg). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure (mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" spread="1.37"/>
                    <measurement group_id="O2" value="-3.18" spread="1.93"/>
                    <measurement group_id="O3" value="0.22" spread="2.26"/>
                    <measurement group_id="O4" value="-0.24" spread="1.96"/>
                    <measurement group_id="O5" value="0.08" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure (mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.88"/>
                    <measurement group_id="O2" value="-3.60" spread="1.25"/>
                    <measurement group_id="O3" value="-0.07" spread="1.46"/>
                    <measurement group_id="O4" value="1.88" spread="1.26"/>
                    <measurement group_id="O5" value="0.77" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs: Pulse Rate at 5 Weeks</title>
        <description>Pulse rate was measured in beats per minute (bpm). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs: Pulse Rate at 5 Weeks</title>
          <description>Pulse rate was measured in beats per minute (bpm). LS Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="1.05"/>
                    <measurement group_id="O2" value="-3.60" spread="1.49"/>
                    <measurement group_id="O3" value="0.87" spread="1.72"/>
                    <measurement group_id="O4" value="1.47" spread="1.51"/>
                    <measurement group_id="O5" value="1.66" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Electrocardiogram Change in Heart Rate Using Bazett's (QTcB) and Fridericia's (QTcF) Formulas</title>
        <description>The number of participants having QTcF and QTcB change ≥ 30 msec was summarized.</description>
        <time_frame>Baseline through 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram Change in Heart Rate Using Bazett's (QTcB) and Fridericia's (QTcF) Formulas</title>
          <description>The number of participants having QTcF and QTcB change ≥ 30 msec was summarized.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcB ≥30 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF ≥30 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Reported Hypoglycemic Events</title>
        <description>Percentage of participants who reported hypoglycemic (lower than normal level of blood glucose) episodes was summarized as other non-serious adverse events (AEs) from the &quot;Investigations&quot; system organ class (preferred term = hypoglycemia). A listing of AEs is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline through 5 weeks</time_frame>
        <population>The safety analysis population included all 273 participants randomized to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) twice daily (BID) oral (po) for 1 week.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg twice daily (BID) oral (po) during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg twice daily (BID) oral (po) during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reported Hypoglycemic Events</title>
          <description>Percentage of participants who reported hypoglycemic (lower than normal level of blood glucose) episodes was summarized as other non-serious adverse events (AEs) from the &quot;Investigations&quot; system organ class (preferred term = hypoglycemia). A listing of AEs is located in the Reported Adverse Event module.</description>
          <population>The safety analysis population included all 273 participants randomized to study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Total Quick Inventory of Depressive Symptomatology (QIDS) Score</title>
        <description>The QIDS was a 16-item patient-rated measure of depressive symptomatology. Each item had a 0 to 3 point scale. The total score ranged from 0 to 27 with higher scores indicative of greater severity. QIDS was calculated by summing the scores from the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) major depressive disorder criteria: depressed mood, loss of interest or pleasure, concentration/decision making, self outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, and psychomotor changes.</description>
        <time_frame>Baseline, 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Total Quick Inventory of Depressive Symptomatology (QIDS) Score</title>
          <description>The QIDS was a 16-item patient-rated measure of depressive symptomatology. Each item had a 0 to 3 point scale. The total score ranged from 0 to 27 with higher scores indicative of greater severity. QIDS was calculated by summing the scores from the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) major depressive disorder criteria: depressed mood, loss of interest or pleasure, concentration/decision making, self outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, and psychomotor changes.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="0.22"/>
                    <measurement group_id="O2" value="-1.49" spread="0.31"/>
                    <measurement group_id="O3" value="-0.69" spread="0.34"/>
                    <measurement group_id="O4" value="-0.46" spread="0.31"/>
                    <measurement group_id="O5" value="0.20" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suicidal Behaviors and Ideations</title>
        <description>The Columbia Suicide Severity Rating Scale (C-SSRS) captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors and ideations were provided. Suicidal behavior = a &quot;yes&quot; answer to any 1 of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation = a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions, which included the wish to be dead and 4 different categories of active suicidal ideation.</description>
        <time_frame>Baseline through week 5</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suicidal Behaviors and Ideations</title>
          <description>The Columbia Suicide Severity Rating Scale (C-SSRS) captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors and ideations were provided. Suicidal behavior = a &quot;yes&quot; answer to any 1 of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation = a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions, which included the wish to be dead and 4 different categories of active suicidal ideation.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal behaviors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Blurry or Hazy Vision Using the Subjective Vision Inventory (SVI) Question 1 (Q1) at 5 Weeks</title>
        <description>This scale first asked if the participant was experiencing hazy or blurry vision or if he/she had difficulty focusing. If the answer was yes, follow-up questions rated the degree to which the issue impaired his/her ability to do work or to read.</description>
        <time_frame>Week 5</time_frame>
        <population>The analysis population was a modified intent to treat (ITT) population defined as participants who received either study drug with only postbaseline data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Blurry or Hazy Vision Using the Subjective Vision Inventory (SVI) Question 1 (Q1) at 5 Weeks</title>
          <description>This scale first asked if the participant was experiencing hazy or blurry vision or if he/she had difficulty focusing. If the answer was yes, follow-up questions rated the degree to which the issue impaired his/her ability to do work or to read.</description>
          <population>The analysis population was a modified intent to treat (ITT) population defined as participants who received either study drug with only postbaseline data collected.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter: Clearance of LY545694 (CLp) and Compound 645838 (CLm)</title>
        <description>Clearance is the volume of plasma cleared of study drug LY545694 (CLp) and metabolite compound 645838 (CLm) per unit time. The original PK/pharmacodynamic (PD) relationship outcome measure analysis was not conducted; therefore, only PK data were reported.</description>
        <time_frame>Baseline through 5 weeks</time_frame>
        <population>The PK dataset for population modeling consisted of quantifiable plasma LY545694 and Compound 64538 concentrations from participants following daily oral doses of LY545694 21 mg to LY545694 105 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>LY545694 Clearance (CLp)</title>
            <description>Plasma LY545694 concentrations were obtained following daily oral doses of LY545694 21 mg to LY545694 105 mg.</description>
          </group>
          <group group_id="O2">
            <title>Compound 645838 (CLm)</title>
            <description>Plasma Compound 645838 concentrations were obtained following daily oral doses of LY545694 21 mg to 105 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Clearance of LY545694 (CLp) and Compound 645838 (CLm)</title>
          <description>Clearance is the volume of plasma cleared of study drug LY545694 (CLp) and metabolite compound 645838 (CLm) per unit time. The original PK/pharmacodynamic (PD) relationship outcome measure analysis was not conducted; therefore, only PK data were reported.</description>
          <population>The PK dataset for population modeling consisted of quantifiable plasma LY545694 and Compound 64538 concentrations from participants following daily oral doses of LY545694 21 mg to LY545694 105 mg.</population>
          <units>Liters per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" lower_limit="68.7" upper_limit="91.9"/>
                    <measurement group_id="O2" value="39.8" lower_limit="35.8" upper_limit="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time to response=first visit achieving a 30% reduction of weekly mean 24-hour APS score. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The number of days at which 50% of the participants at risk had at least 30% response was reported.</description>
        <time_frame>Baseline through 5 weeks</time_frame>
        <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time to response=first visit achieving a 30% reduction of weekly mean 24-hour APS score. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). The number of days at which 50% of the participants at risk had at least 30% response was reported.</description>
          <population>The analysis population was a modified intent-to-treat (ITT) population defined as participants who received either study drug with both baseline and at least 1 postbaseline measure.</population>
          <units>time (days)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neurological Treatment Emergent Adverse Events (TEAEs)</title>
        <description>The total number of TEAEs (serious and non-serious) that first occurred or worsened during the treatment period) from the &quot;Nervous system disorders&quot; system organ class was summarized. A listing of serious AEs (SAEs) and other non-serious AEs is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline through 5 weeks</time_frame>
        <population>The safety analysis population included all 273 participants randomized to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Pregabalin thrice daily TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6.</description>
          </group>
          <group group_id="O3">
            <title>LY545694 21 mg</title>
            <description>LY545694 21 milligrams (mg) BID po for 1 week.</description>
          </group>
          <group group_id="O4">
            <title>LY545694 49 mg</title>
            <description>LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
          </group>
          <group group_id="O5">
            <title>LY545694 105 mg</title>
            <description>LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neurological Treatment Emergent Adverse Events (TEAEs)</title>
          <description>The total number of TEAEs (serious and non-serious) that first occurred or worsened during the treatment period) from the &quot;Nervous system disorders&quot; system organ class was summarized. A listing of serious AEs (SAEs) and other non-serious AEs is located in the Reported Adverse Event module.</description>
          <population>The safety analysis population included all 273 participants randomized to study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules three times daily (TID) po for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>LY545694 21 mg</title>
          <description>LY545694 21 milligrams (mg) twice daily (BID) oral (po) for 1 week</description>
        </group>
        <group group_id="E3">
          <title>LY545694 49 mg</title>
          <description>LY545694 escalated to 49 mg twice daily (BID) oral (po) during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.</description>
        </group>
        <group group_id="E4">
          <title>LY545694 105 mg</title>
          <description>LY545694 escalated to 105 mg twice daily (BID) oral (po) during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.</description>
        </group>
        <group group_id="E5">
          <title>Pregabalin</title>
          <description>Pregabalin thrice daily (TID) oral (po) for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6</description>
        </group>
        <group group_id="E6">
          <title>Placebo Washout</title>
          <description>A one-week washout period in which no placebo was taken.</description>
        </group>
        <group group_id="E7">
          <title>LY545694 21 mg Washout</title>
          <description>A one-week washout period in which no LY545694 21 mg was taken.</description>
        </group>
        <group group_id="E8">
          <title>LY545694 49 mg Washout</title>
          <description>A one-week washout period in which no LY545694 49 mg was taken.</description>
        </group>
        <group group_id="E9">
          <title>LY545694 105 mg Washout</title>
          <description>A one-week washout period in which no LY545694 105 mg was taken.</description>
        </group>
        <group group_id="E10">
          <title>Pregabalin Washout</title>
          <description>A one-week washout period in which no pregabalin was taken.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Phosphenes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Retinal exudates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lip disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="89"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E4" events="14" subjects_affected="12" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bicarbonate abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Electrocardiogram poor r-wave progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qrs complex prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Electrocardiogram t wave abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Grip strength decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Monofilament pressure perception test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neurological examination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Qrs axis abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rheumatoid factor increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypocholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Salt craving</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vitamin d deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Posture abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Decreased vibratory sense</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyporeflexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Narcolepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dissociation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Elevated mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Terminal insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder sphincter atony</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pleural rub</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Renal stone removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Skin graft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tumour excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

